نتایج جستجو برای: beta interferon 1a
تعداد نتایج: 277060 فیلتر نتایج به سال:
Background Several disease-modifying drug therapies are available for the treatment of multiple sclerosis (MS). To ensure the most appropriate MS management, we assessed the effectiveness and cost-effectiveness of the disease-modifying medicines used for MS. Methods We conducted a systematic review including 11 disease-modifying drugs used for treatment of adult patients diagnosed with relaps...
The review by Goodin and Bates in this issue 1 on treating multiple sclerosis (MS) when it might first be heralding is indeed timely for a number of reasons. First, virtually all of the first line current disease modifying drugs (interferon beta and glatiramer acetate) have now been shown to be effective at the stage called 'CIS' or the first 'clinically isolated syndrome' in reducing the chanc...
conclusions it can be concluded that the rsm is an effective method for the optimization of recombinant protein expression using synthetic genes in e. coli. results the proposed optimum fermentation condition consisted of 7.81 g l-1 glucose, od 600 nm prior induction 1.66 and induction temperature of 30.27°c. the model prediction of 0.267 g l-1 of rhifn-β and 0.961 g l-1 of acetate at the optim...
no abstract
Background: Interferons are some kind of natural cytokines which express in response to a variety of antigens including viral RNA, bacterial products, and tumor proteins. Interferon beta is used in the treatment of autoimmune diseases such as multiple sclerosis. Moreover, this drug inhibits cellular proliferation as well as angiogenesis and as a result, helps to cure cancer. In this research, i...
OBJECTIVE To investigate whether ω-3 fatty acids reduce magnetic resonance imaging (MRI) and clinical disease activity in patients with multiple sclerosis, both as monotherapy and in combination with interferon beta-1a treatment. DESIGN Multicenter, randomized, double-blind, placebo-controlled clinical trial conducted from 2004 to 2008. SETTING Thirteen public neurology departments in Norwa...
Interferon (INF) beta 1a 22 or 44 mug (Rebif((R))) administered s.c. 3 times a week (t.i.w) is a well established immunomodulating treatment for relapsing remitting multiple sclerosis (RRMS). This review focuses on its mechanisms of action, evidence of efficacy, safety, and tolerability. Several pharmacodynamic properties explain the immunomodulatory actions of INF beta 1a 22 or 44 mug s.c. t.i...
BACKGROUND Crohn's disease (CD) and multiple sclerosis (MS) share common pathogenic processes. Interferon (IFN) beta-1a is effective and generally well tolerated in patients with MS and has been shown to down-regulate the expression of interleukin-12, a cytokine that is thought to be involved in mucosal degeneration in CD. IFN beta-1a therefore offers promise as a treatment for CD. METHODS In...
OBJECTIVE To evaluate whether recombinant human interferon-beta-1a significantly affects disease activity as measured by a reduction in the number and volume of Gd enhancing lesions on monthly MRI. The study also evaluated the effect on six-monthly T2 weighted abnormality and relapse frequency. METHODS After a baseline scan and a six month pretreatment period, 68 patients were randomly assign...
نمودار تعداد نتایج جستجو در هر سال
با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید